Emsam (Selegiline) Patent Expiration, LOE Window & CMS Spending

Emsam (Selegiline) by Somerset: Off-Patent Genericized (AB Competition), 5 AB generics, $17.2M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSomerset
FDA Application & PathwayN021336 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$17.2M
2024 Medicare Part D Spend$12.5M
2024 Medicaid Spend$4.6M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 18.0% 2-yr change)